Cyclacel Pharmaceuticals Files 8-K: Operations, Officers, Financials
Ticker: BGMSP · Form: 8-K · Filed: Apr 2, 2025 · CIK: 1130166
Sentiment: neutral
Topics: operations, financials, officer-changes
Related Tickers: CYCC
TL;DR
Cyclacel dropped an 8-K detailing Q1 results, exec changes, and financials. Check it out.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed an 8-K on April 2, 2025, reporting events as of March 31, 2025. The filing covers results of operations, financial condition, director and officer changes, and includes financial statements and exhibits. It also notes a former company name, XCYTE THERAPIES INC, with a name change date of December 18, 2000.
Why It Matters
This 8-K filing provides crucial updates on Cyclacel Pharmaceuticals' operational and financial status, as well as any changes in its leadership, which are important for investors to monitor.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant information about a company's financial health and strategic direction, which may impact its stock price.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- XCYTE THERAPIES INC (company) — Former company name
- March 31, 2025 (date) — Date of earliest event reported
- April 2, 2025 (date) — Filing date
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates 'Results of Operations and Financial Condition' are being reported, but the specific financial figures are not detailed in the provided header information.
Were there any changes in directors or officers reported?
Yes, the filing explicitly lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item covered.
What is the primary business of Cyclacel Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code provided is 'PHARMACEUTICAL PREPARATIONS [2834]', indicating their business is in pharmaceutical preparations.
When did Cyclacel Pharmaceuticals, Inc. change its name from XCYTE THERAPIES INC?
The name change from XCYTE THERAPIES INC to Cyclacel Pharmaceuticals, Inc. occurred on December 18, 2000.
What is the filing date of this 8-K report?
This 8-K report was filed on April 2, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 2, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).